PPV-06 Vaccine in Inflammatory Knee Osteoarthritis

Trial details

Who runs it

Peptinov SAS

Trial code

NCT06605963

Record updated

2 November 2026

Original description

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process.Read full original descriptionShow less

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients With Inflammatory Knee Osteoarthritis (KOA)

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process.

The goal of this clinical trial is to test the safety and efficacy of PPV-06 in participants with Knee Osteoarthritis. The main questions are to evaluate if PPV-06 can reduce pain and improve functioning in participants with knee osteoarthritis, and to evaluate if ¨PPV-06 is safe when administered to participants.

Participants will be administered with 6 subcutaneous injections of either PPV-06 or placebo, over a two-year period.

Inclusion: Participant has given written informed consent to participate; Male or female, aged at least 40 years old; BMI between 22 to 35kg/m² at Screening visit; Diagnosis of osteoarthritis of the index knee based on American College of Rheumatology (ACR) criteria and functional capacity class of I-III, with a Kellgren-Lawrence grade [KLG] 2 or 3; OARSI medial Joint Space Narrowing (mJSN) Grade 1 or 2 of the index knee joint, confirmed by a semi-flexed or fixed flexion weight-bearing X-Ray performed at Screening visit, and assessed by Central Reader; Evidence during the Screening visit of synovitis in the index knee based on ultrasound as described in the Ultrasound Doppler manual; Evidence of moderate to severe Synovitis on 11-point synovitis (based on Guermazi et al. score), as assessed by Rapid OA MRI Eligibility Score (ROAMES(1)), per-formed during the Screening visit and assessed by Central Reader; Insufficient pain relief with standard of care (i.e. non-pharmacological treat-ments, systemic non-steroidal anti-inflammatory drugs (NSAIDs) and/or other analgesics) for symptomatic OA in the index knee within 6 months prior to the Screening vis-it; Pain at index knee for the majority of days (>50%) during the preceding month prior to the Screening Visit; At Screening Visit 1a, participant reports that their typical OA knee pain in one or both knees when not using medication is ≥ 4 out of 10; WOMAC pain subscale score (5 items) in the range [≥4 and ≤8], using the 11-point (0-10) NRS for the index knee at Screening and Baseline visits; Participant is willing to discontinue all pain medications for OA except rescue medication (pa-racetamol), to adhere to the restricted use of concomitant treatments and not use prohibited pain medications throughout the clinical trial.

Exclusion: Participant had an administration of NSAID (topical, tablets) or Cox-2 Inhibitors within 2 weeks prior to the Baseline visit; Injection of either corticosteroid or intra-articular (IA) Visco-supplementation (i.e., hyaluronic acid) into the index knee within 1 month of Screening; Past joint replacement surgery of the index knee; Scheduled surgery except dental surgery during the clinical trial period; Systemic (except inhaled) immunosuppressant agent within 6 months prior to trial medication administration; Evidence or history of severe psychiatric illness/disorder during 3 years prior to the Screening Visit that, in the investigator's opinion, may affect safety or efficacy assess-ments or may compromise the patient's safety during trial participation; History of significant trauma or surgery (e.g., open or arthroscopic) to the in-dex knee within 12 months of Screening; Any known active infection, including suspicion of intra-articular infection, ul-cer or open wound anywhere on the index knee; Known presence of pre-existing MRI-based findings warranting exclusion in accordance with the ROAMES criteria, such as rapidly progressing osteoarthritis (RPOA) Type I or Type II, osteonecrosis, subchondral insufficiency fracture, atrophic oste-oarthritis, severe bone on bone osteoarthritis, or knee pain attributable to disease other than osteoarthritis, or as assessed by X-Ray, based on Central imaging Reading at Screening Visit and before the Baseline Visit; Other conditions that could affect trial endpoint assessments of the index knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, ankylosing spondyli-tis, gout or pseudogout, inflammatory bowel disease related arthropathy, peripheral neuropathy, lupus erythematosus, significant skin conditions such as abscesses, acromegaly, metabolic joint diseases and fibromyalgia; Current clinically significant disease(s) or condition(s) (including clinically significant cardiovascular disease and/or significant pain in other areas) that may affect efficacy or safety assessments, or any other reason which, in the investigator's opinion, may preclude the patient's participation in the full duration of the trial; Major bleeding disorder encompassing, but not limited to coagulopathy and any current antithrombotic and anticoagulant events; History of severe allergic or anaphylactic reactions; Known infection of human immunodeficiency virus (HIV), or known current acute or chronic hepatitis B or C infection; History of malignancy within 5 years prior to the Screening visit, with the ex-ception of basal cell carcinoma; History of either active TB or latent TB with inadequate course of anti-tuberculous prophylaxis; Injection of platelet-rich plasma (PRP) into the index knee within 6 months of Screening; Contraindications to an MRI (including the gadolinium contrast with a Glo-merular Filtration Rate (GFR) below 60 mL/min) of the index knee or has a pacemaker or any other implanted electronic devices. Claustrophobic patient with impossibility to under-go an MRI; Application of topical capsaicin on the index knee within 1 month of Screening; Periarticular pain from any cause other than osteoarthritis, including referred pain, bursitis, tendinitis, soft tissue tenderness, or subacute/acute pain from injury in the index knee; Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the index knee (varus >10°, valgus >10°) by X-Ray as assessed by Central Readers at Screening Visit; Neuropathic pain as assessed by PainDETECT questionnaire with a score of at least 18 at Screening Visit; Unstable or poorly controlled blood pressure which, in the opinion of the inves-tigator, would put the patient at risk of severe adverse blood pressure increases upon IMP administration; Known or suspected of not being able to comply with the requirements of the trial protocol or the instructions of the trial site staff.

ClinicalTrials.gov NCT06605963